Evidence map›Paper›PMID 38927976›Full record

ArticleCancers2024

Distance of Biopsy-Confirmed High-Risk Breast Lesion from Concurrently Identified Breast Malignancy Associated with Risk of Carcinoma at the High-Risk Lesion Site.

Julie Le, Thomas J O'Keefe, Sohini Khan, Sara M Grossi, Hye Young Choi, Haydee Ojeda-Fournier, Ava Armani, Anne M Wallace, Sarah L Blair

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Julie LeDivision of Breast Surgery, The Comprehensive Breast Health Center, University of California San Diego, 3855 Health Sciences Dr, La Jolla, CA 92093, USA.
Thomas J O'KeefeDepartment of Surgery, Jennifer Moreno Department of Veterans Affairs Medical Center, La Jolla, CA 92161, USA.
Sohini KhanDepartment of Surgery, University of California San Diego, 3855 Health Sciences Dr, La Jolla, CA 92093, USA.
Sara M GrossiDivision of Breast Surgery, The Comprehensive Breast Health Center, University of California San Diego, 3855 Health Sciences Dr, La Jolla, CA 92093, USA.ORCID 0000-0001-5851-4627
Hye Young ChoiDivision of Breast Imaging, University of California San Diego, 3855 Health Sciences Dr, La Jolla, CA 92093, USA.ORCID 0000-0002-3714-5700
Haydee Ojeda-FournierDivision of Breast Imaging, University of California San Diego, 3855 Health Sciences Dr, La Jolla, CA 92093, USA.ORCID 0000-0003-3773-0050
Ava ArmaniDivision of Breast Surgery, The Comprehensive Breast Health Center, University of California San Diego, 3855 Health Sciences Dr, La Jolla, CA 92093, USA.ORCID 0000-0003-3731-2182
Anne M WallaceDivision of Breast Surgery, The Comprehensive Breast Health Center, University of California San Diego, 3855 Health Sciences Dr, La Jolla, CA 92093, USA.
Sarah L BlairDivision of Breast Surgery, The Comprehensive Breast Health Center, University of California San Diego, 3855 Health Sciences Dr, La Jolla, CA 92093, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-risk breast lesions including incidental intraductal papilloma without atypia (IPA), lobular hyperplasia (LCIS or ALH), flat epithelial atypia (FEA) and complex sclerosing lesion (CSL) are not routinely excised due to low upgrade rates to carcinoma. We aim to identify features of these lesions predictive of upgrade when identified concurrently with invasive disease. Methods: A single-center retrospective cohort study was performed for patients who underwent multi-site lumpectomies with invasive disease at one site and a high-risk lesion at another site between 2006 and 2021. A multinomial logistic regression was performed. Results: Sixty-five patients met the inclusion criteria. Four patients (6.2%) had an upgrade to in situ disease (DCIS) and one (1.5%) to invasive carcinoma. Three upgraded high-risk lesions were ipsilateral to the concurrent carcinoma and two were contralateral. In the multivariate model, a high-risk lesion within 5 cm of an ipsilateral malignancy was associated with increased risk of upgrade. The 3.8% upgrade rate for high-risk lesions located greater than 5 cm from ipsilateral malignancy or in the contralateral breast suggests that omission of excisional biopsy may be considered. Excisional biopsy of lesions within 5 cm of ipsilateral malignancy is recommended given the 25% upgrade risk in our series.

Indexed as

breast cancercomplex sclerosing lesion of breastflat epithelial atypiahigh-risk breast lesionintraductal papillomalobular hyperplasiasynchronous breast cancer

Identifiers

PMID38927976
PMCPMC11201489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.